Overview

NCI Definition [1]:
A radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90, with potential antineoplastic activities. Upon administration, the antibody moiety of yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101 binds to CDH3 expressed on tumor cells, thereby specifically delivering cytotoxic beta radiation to CDH3-expressing tumor cells. CDH3, also known as P-cadherin, is a tumor-associated antigen (TAA) and member of the cadherin family; it is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.

Ff-21101 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ff-21101, 1 is phase 1 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for ff-21101 clinical trials.

Breast carcinoma, cholangiocarcinoma, and colorectal carcinoma are the most common diseases being investigated in ff-21101 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ff-21101
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ff-21101 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
yttrium y 90 anti-cdh3 monoclonal antibody ff-21101, ff-21101(90y), yttrium y 90 anti-cdh3 monoclonal antibody ff-21101
Drug Target(s) [2]:
CDH3
NCIT ID [1]:
C122405

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.